Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis

Kevin Winthrop, S. H. Park, A. Gul, M. H. Cardiel, J. J. Gomez-Reino, Y. Tanaka, K. Kwok, T. Lukic, E. Mortensen, D. Ponce de Leon, R. Riese, H. Valdez

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

Objectives To evaluate the risk of opportunistic infections (OIs) in patients with rheumatoid arthritis (RA) treated with tofacitinib. Methods Phase II, III and long-term extension clinical trial data (April 2013 data-cut) from the tofacitinib RA programme were reviewed. OIs defined a priori included mycobacterial and fungal infections, multidermatomal herpes zoster and other viral infections associated with immunosuppression. For OIs, we calculated crude incidence rates (IRs; per 100 patient-years (95% CI)); for tuberculosis (TB) specifically, we calculated rates stratified by patient enrolment region according to background TB IR (per 100 patient-years): low (≥0.01), medium (

Original languageEnglish (US)
JournalAnnals of the Rheumatic Diseases
DOIs
StateAccepted/In press - Aug 28 2015

Fingerprint

Opportunistic Infections
Rheumatoid Arthritis
Tuberculosis
Mycoses
Herpes Zoster
Virus Diseases
Immunosuppression
Clinical Trials
tofacitinib
Incidence

ASJC Scopus subject areas

  • Rheumatology
  • Immunology
  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Allergy

Cite this

Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis. / Winthrop, Kevin; Park, S. H.; Gul, A.; Cardiel, M. H.; Gomez-Reino, J. J.; Tanaka, Y.; Kwok, K.; Lukic, T.; Mortensen, E.; Ponce de Leon, D.; Riese, R.; Valdez, H.

In: Annals of the Rheumatic Diseases, 28.08.2015.

Research output: Contribution to journalArticle

Winthrop, K, Park, SH, Gul, A, Cardiel, MH, Gomez-Reino, JJ, Tanaka, Y, Kwok, K, Lukic, T, Mortensen, E, Ponce de Leon, D, Riese, R & Valdez, H 2015, 'Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis', Annals of the Rheumatic Diseases. https://doi.org/10.1136/annrheumdis-2015-207319
Winthrop, Kevin ; Park, S. H. ; Gul, A. ; Cardiel, M. H. ; Gomez-Reino, J. J. ; Tanaka, Y. ; Kwok, K. ; Lukic, T. ; Mortensen, E. ; Ponce de Leon, D. ; Riese, R. ; Valdez, H. / Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis. In: Annals of the Rheumatic Diseases. 2015.
@article{458da8b85cf14892a5987552f294fa9c,
title = "Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis",
abstract = "Objectives To evaluate the risk of opportunistic infections (OIs) in patients with rheumatoid arthritis (RA) treated with tofacitinib. Methods Phase II, III and long-term extension clinical trial data (April 2013 data-cut) from the tofacitinib RA programme were reviewed. OIs defined a priori included mycobacterial and fungal infections, multidermatomal herpes zoster and other viral infections associated with immunosuppression. For OIs, we calculated crude incidence rates (IRs; per 100 patient-years (95{\%} CI)); for tuberculosis (TB) specifically, we calculated rates stratified by patient enrolment region according to background TB IR (per 100 patient-years): low (≥0.01), medium (",
author = "Kevin Winthrop and Park, {S. H.} and A. Gul and Cardiel, {M. H.} and Gomez-Reino, {J. J.} and Y. Tanaka and K. Kwok and T. Lukic and E. Mortensen and {Ponce de Leon}, D. and R. Riese and H. Valdez",
year = "2015",
month = "8",
day = "28",
doi = "10.1136/annrheumdis-2015-207319",
language = "English (US)",
journal = "Annals of the Rheumatic Diseases",
issn = "0003-4967",
publisher = "BMJ Publishing Group",

}

TY - JOUR

T1 - Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis

AU - Winthrop, Kevin

AU - Park, S. H.

AU - Gul, A.

AU - Cardiel, M. H.

AU - Gomez-Reino, J. J.

AU - Tanaka, Y.

AU - Kwok, K.

AU - Lukic, T.

AU - Mortensen, E.

AU - Ponce de Leon, D.

AU - Riese, R.

AU - Valdez, H.

PY - 2015/8/28

Y1 - 2015/8/28

N2 - Objectives To evaluate the risk of opportunistic infections (OIs) in patients with rheumatoid arthritis (RA) treated with tofacitinib. Methods Phase II, III and long-term extension clinical trial data (April 2013 data-cut) from the tofacitinib RA programme were reviewed. OIs defined a priori included mycobacterial and fungal infections, multidermatomal herpes zoster and other viral infections associated with immunosuppression. For OIs, we calculated crude incidence rates (IRs; per 100 patient-years (95% CI)); for tuberculosis (TB) specifically, we calculated rates stratified by patient enrolment region according to background TB IR (per 100 patient-years): low (≥0.01), medium (

AB - Objectives To evaluate the risk of opportunistic infections (OIs) in patients with rheumatoid arthritis (RA) treated with tofacitinib. Methods Phase II, III and long-term extension clinical trial data (April 2013 data-cut) from the tofacitinib RA programme were reviewed. OIs defined a priori included mycobacterial and fungal infections, multidermatomal herpes zoster and other viral infections associated with immunosuppression. For OIs, we calculated crude incidence rates (IRs; per 100 patient-years (95% CI)); for tuberculosis (TB) specifically, we calculated rates stratified by patient enrolment region according to background TB IR (per 100 patient-years): low (≥0.01), medium (

UR - http://www.scopus.com/inward/record.url?scp=84941588323&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941588323&partnerID=8YFLogxK

U2 - 10.1136/annrheumdis-2015-207319

DO - 10.1136/annrheumdis-2015-207319

M3 - Article

C2 - 26318385

AN - SCOPUS:84941588323

JO - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

SN - 0003-4967

ER -